Syndax Pharmaceuticals Shares Drop After Phase 2 Trial Failure for Axatilimab
Shares of Syndax Pharmaceuticals (NASDAQ: SNDX) fell approximately 15% after-hours on Monday following the announcement that its experimental drug axatilimab failed to meet its primary endpoint in a phase 2 clinical trial. The treatment, intended for idiopathic pulmonary fibrosis (IPF), did not achieve the target of reducing the annualized rate of decline in forced vital capacity. The failure marks a setback for Syndax's pipeline and could impact investor confidence in the company’s ability to deliver on its therapeutic candidates. Axatilimab was being developed as an anti-angiogenic therapy, aiming to slow disease progression by targeting blood vessel growth associated with IPF.
Tickers: $SNDX